all news

Massachusetts Biomedical Initiatives (MBI) Highlights Worcester’s Leading Life Sciences Job Growth, Accelerator Milestones, and Company Expansions in Third Quarter of 2026

October 22, 2026 / press release

Massachusetts Biomedical Initiatives (MBI) Highlights Worcester’s Leading Life Sciences Job Growth, Accelerator Milestones, and Company Expansions in Third Quarter of 2026 

 

Worcester, MA (October 22, 2026) – Massachusetts Biomedical Initiatives (MBI), a nonprofit dedicated to building the Central Massachusetts life sciences and biomanufacturing ecosystem, marked the third quarter of 2026 with new evidence of the region’s growing industry presence, the completion of its inaugural Auxilium-MBI Accelerator cohort, and significant milestones among companies at its incubator. According to MassBio’s 2026 Industry Snapshot, Worcester County led Massachusetts in life sciences research and development job growth, reinforcing the region’s emergence as a destination for life sciences companies and talent. 

“Central Mass is showing what happens when talented founders have access to the right infrastructure, capital, and connections,” said Jon Weaver, President and CEO of MBI. “The latest MassBio data confirms the momentum we’re seeing firsthand. Companies are expanding their operations here, attracting investment, and advancing technologies with global applications. Our focus is on making sure they have the support to keep growing and set down roots in Central Mass.” 

Worcester Leads Massachusetts in Life Sciences R&D Job Growth 

MassBio’s 2026 Industry Snapshot identified Worcester County as the fastest-growing county in Massachusetts for life sciences research and development employment. R&D jobs increased 6.7%, from 2,896 to 3,091 positions, outpacing every other county in the Commonwealth. Worcester is also home to 54 MassBio member companies, putting it on par with established life sciences centers in the state such as Waltham and Natick. 

The findings reflect Central Mass’ growing role in the state’s life sciences economy and reinforce the need for continued investment in the infrastructure, workforce, and resources that allow companies to launch and scale locally. This growth aligns with MBI’s Regional Biomanufacturing Strategy, which outlines a coordinated approach to strengthening the region’s biomanufacturing capacity and supporting long-term industry growth. 

Inaugural Auxilium-MBI Accelerator Cohort Completes Program 

Four life sciences and healthcare startups completed the inaugural Auxilium-MBI Accelerator, a joint initiative between Auxilium Worcester and MBI designed to connect early-stage companies with investment, mentorship, and industry expertise. 

The participating companies—CPR Therapeutics, Microvitality, Predictive Healthcare, and SilkMed—concluded the program by presenting their businesses to investors, mentors, partners, and community members. 

Launched in the second quarter of 2026, the three-month accelerator provided participating companies with $250,000 in seed investment per company, access to MBI’s incubation facilities, mentorship from industry veterans, and sector-specific programming. The completion of this cohort marks another step toward building a stronger pipeline of life sciences companies with the resources and relationships needed to grow in Central Massachusetts. 

New Incubator Tenant and Company Expansions 

MBI welcomed Boston MycoTech to its StartUp Center at 60 Prescott Street in Worcester and Dualys Bio to its 17 Briden Street location during the third quarter. Boston MycoTech occupies a 366-square-foot laboratory and specializes in precision fermentation for specialty molecules, combining microbial engineering and downstream processing to produce high-purity compounds at commercial scale. Dualys is developing a programmable intracellular proteolysis platform designed to selectively cleave disease-driving proteins inside cells. 

Two additional companies expanded into larger laboratory spaces at MBI in September: 

  • XTOP Biotherapeutics moved into a 663-square-foot laboratory to advance its CrossBody immuno-oncology platform. 
  • Volta Energy moved into a 733-square-foot laboratory to advance its clean energy storage technology. 

The expansions demonstrate how MBI’s flexible laboratory infrastructure allows companies to increase their space as their research and business needs evolve, while remaining connected to the region’s life sciences ecosystem. 

Incubator Companies Secure Federal Funding 

Companies at MBI also achieved significant funding milestones during the quarter: 

  • Eascra Biotech was awarded a $7.96 million NASA In-Space Production Applications (InSPA) Phase 2 contract in August to advance commercialization of low Earth orbit manufacturing of its Janus Base Nanoparticles. The award builds on Eascra’s six missions to the International Space Station in under three years and supports the company’s efforts to translate space-based research into commercial manufacturing capabilities. 
  • Waterfall Scientific received a $54.5 million award from the Advanced Research Projects Agency for Health (ARPA-H) through the Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) initiative. Waterfall Scientific will lead a consortium of partners including Ansa Biotechnologies, Volta Labs, Polymorphic Biosciences, Tensentric and Ginkgo Bioworks to develop a continuous-flow, cell-free mRNA manufactuiring and characterization platform. Other Regional Updates that Underscore Growing Momentum 

MBI continued to strengthen regional partnerships, support entrepreneurs, and advance conversations around Central Massachusetts’ life sciences future throughout the third quarter: 

  • Dr. Marsha Rolle was promoted to Vice President of Strategic Programs at MBI in August. Previously Director of Advancement, Rolle will lead the organization’s workforce development, regional economic growth, advancement, and marketing initiatives. 
  • Congressman Jim McGovern, a longtime advocate for the region, visited MBI to continue discussions initiated during the NIIMBL National Meeting in Washington, D.C., about building the infrastructure needed to support life sciences growth in Central Massachusetts. 
  • Congressman Jake Auchincloss, a champion for federral life science research funding, also visited MBI during the quarter as part of a trip to Worcester that included UMass Chan Medical School.  
  • Jon Weaver, President and CEO of MBI, participated in the Central Massachusetts Regional Planning Commission’s 50th anniversary Quarterly Commission meeting in September, discussing the region’s economic future and the potential of Worcester Regional Airport to support biomanufacturing logistics. 

MBI’s StartUp & ScaleUp incubator model bridges the gap between early-stage launch and commercial growth. The StartUp space offers small, private laboratories for founders to validate concepts and launch companies. As they grow, companies can transition to ScaleUp facilities with larger laboratories and private office suites designed for expanding teams and operations. MBI’s Pilot Biomanufacturing Center also provides facilities designed to support early-stage clinical manufacturing. Together, these resources allow companies to access right-sized space as they grow, while opening opportunities for new startups to enter the region’s life sciences pipeline. 

### 

 

 

About Massachusetts Biomedical Initiatives 

MBI is a non-profit focused on building the Central Massachusetts bio-cluster. MBI’s mission is to be a partner for fostering innovation in the life sciences and achieves that goal through its small business incubator system, workforce development efforts, and regional economic development initiatives. It is estimated that since 2000, MBI has assisted over 197 companies that have created over 1,800 jobs resulting in a $2 billion economic impact. 

Media Contact: 

Alicia Curran, acurran@aliciacurrancommunications.com, cell: 407-797-2076